Dr. Manji on Treatment for BRAF-Mutant CRC

Gulam A. Manji, MD, PhD
Published: Friday, Aug 16, 2019



Gulam A. Manji, MD, PhD, director, Medical Oncology and Translational Research for The Pancreas Center, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, discusses clinical trials for patients with colorectal cancer (CRC) harboring BRAF or other molecular abnormalities.

Although prognosis is poor for patients with BRAF-mutant CRC, recent combination trials that target EGFR, MAK, and BRAF mutations are showing intriguing clinical activity, according to Manji.

Manji recommends that all patients with CRC who have BRAF mutations and other abnormalities should enroll onto biomarker-driven clinical trials to help researchers get solid data that show proven benefit.
SELECTED
LANGUAGE


Gulam A. Manji, MD, PhD, director, Medical Oncology and Translational Research for The Pancreas Center, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, discusses clinical trials for patients with colorectal cancer (CRC) harboring BRAF or other molecular abnormalities.

Although prognosis is poor for patients with BRAF-mutant CRC, recent combination trials that target EGFR, MAK, and BRAF mutations are showing intriguing clinical activity, according to Manji.

Manji recommends that all patients with CRC who have BRAF mutations and other abnormalities should enroll onto biomarker-driven clinical trials to help researchers get solid data that show proven benefit.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x